XOMA Corp (XOMA)

Currency in USD
40.17
-4.05(-9.16%)
Closed·
Showing XOMA historical data. For real-time data please try another search
Fair Value
Day's Range
39.7743.97
52 wk Range
22.2945.22
Key Statistics
Prev. Close
40.17
Open
43.97
Day's Range
39.77-43.97
52 wk Range
22.29-45.22
Volume
6.71M
Average Volume (3m)
341.16K
1-Year Change
50.9583%
Book Value / Share
7.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XOMA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
39.00
Downside
-2.91%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

XOMA Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 39.00
(-2.91% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

XOMA Corp Earnings Call Summary for Q4/2025

  • XOMA Q4 2025 EPS of $0.26 beat forecast of -$0.11 by 336%; revenue reached $13.76M, exceeding estimates by 23.63%
  • Full-year revenue surged 82.8% vs 2024; GAAP net income of $31.7M reversed prior year's $13.8M loss; royalty receipts up 68% to $34M
  • Stock climbed 5.19% to $28.40 in pre-market trading following the earnings beat, reflecting strong investor confidence
  • Company projects continued growth in 2026 driven by diversified portfolio and strategic capital deployment initiatives
  • Key risks include ongoing Janssen Biotech litigation and declining cash reserves from strategic investments despite debt reduction efforts
Last Updated: 2026-03-18, 10:18 a/m
Read Full Transcript

Earnings

Latest Release
Apr 30, 2026
EPS / Forecast
0.17 / 0.04
Revenue / Forecast
13.91M / 12.97M
EPS Revisions
Last 90 days

XOMA Income Statement

Compare XOMA to Peers and Sector

Metrics to compare
XOMA
Peers
Sector
Relationship
P/E Ratio
35.6x−1.3x−0.4x
PEG Ratio
0.14−0.460.00
Price/Book
7.7x3.3x2.6x
Price / LTM Sales
14.6x13.3x3.1x
Upside (Analyst Target)
−2.9%95.9%51.8%
Fair Value Upside
Unlock0.9%7.5%Unlock

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.39M27.00%136.03M
Other Institutional Investors
21.58M73.00%866.84M
Public Companies & Retail Investors
0.000.00%0.00
Total
24.97M100.00%1B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BVF Partners L.P.60.55%7,593,303305,023
Biotechnology Value Fund L.P.28.99%3,635,758146,048

People Also Watch

254.11
PLXS
-2.40%
28.490
CUE
-8.92%
67.59
KGS
-2.17%
103.00
CMPR
+4.55%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.